Company Dossier · Health Care
Johnson & Johnson
- S&P 500
- S&P 100
- Dow 30
- Russell 1000
What Johnson & Johnson is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 28, 2026: $97.9 billion, up 8.1% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 28, 2026: $22.2 billion, up 20% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 28, 2026: $5.36 billion, up 20% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 28, 2025: $5.95 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 28, 2025: $9.14 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (October 13, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.85 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 2 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 11, 2026): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $67.8 million on the open market.SEC Form 4
- 4,705 institutional managers reported a position at June 30, 2026 (+42 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 162 (104 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Nov 12, 2025 →
Company Posture
How Company Posture is measured →What Johnson & Johnson is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending87th pct
- Debt raised12th pct
- Buybacks vs capex45th pct
- Hiring filings55th pct
- Deals and private raises42nd pct
- Patent publications51st pct
- + Capital spending
- − Debt raised
- − Deals and private raises
Confident ↔ Hedging
Mixed
- Call sentiment65th pct
- Call confidence70th pct
- Guidance changes43rd pct
- Risk factors added9th pct
- Insider open-market trades29th pct
- − Risk factors added
- + Call confidence
- + Call sentiment
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver59th pct
- Stress filings48th pct
Credit
How these are built →Johnson & Johnson's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$44.7B
- Due within a year $8.9B
- Longer term $35.8B
- Default point $26.8B (short + ½ long)
Finance leases included · Sep 27, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Feb 19, 2025 | €600M | 2.700% | 2029 (4y) | +55bp | 2.739% |
| Feb 19, 2025 | €1B | 3.700% | 2055 (30y) | +90bp | 3.706% |
| Feb 19, 2025 | €700M | 3.600% | 2045 (20y) | +83bp | 3.629% |
| Feb 19, 2025 | €1B | 3.350% | 2037 (12y) | +70bp | 3.362% |
| Feb 19, 2025 | €700M | 3.050% | 2033 (8y) | +63bp | 3.082% |
| Feb 18, 2025 | $750M | 4.550% | 2028 (3y) | +25bp | 4.570% |
| Feb 18, 2025 | $750M | 4.500% | 2027 (2y) | +20bp | 4.499% |
| Feb 18, 2025 | $1B | 4.700% | 2030 (5y) | +35bp | 4.745% |
| Feb 18, 2025 | $1.25B | 4.850% | 2032 (7y) | +42bp | 4.898% |
| Feb 18, 2025 | $1.25B | 5.000% | 2035 (10y) | +47bp | 5.016% |
| May 14, 2024 | €800M | 3.350% | 2036 (12y) | +75bp | 3.368% |
| May 14, 2024 | €700M | 3.200% | 2032 (8y) | +73bp | 3.210% |
From the pricing term sheets Johnson & Johnson filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Johnson & Johnson, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NegativeJohnson & Johnson stock rout: What's driving the sharp decline? - J&J stock slides despite higher earnings guidance
economictimes.indiatimes.com · via Marketaux · Oct 14, 2026
- NeutralJohnson & Johnson settles US talcum powder lawsuit with $5.5bn payout
FT Companies · Jul 28, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC))third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (SPLITOAK STRATEGIES LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (JOHNSON & JOHNSON SERVICES, INC.)third_quarter 2026 · $2.2 million
- Oct 20, 2026LobbyingLobbying report (WINNING STRATEGIES WASHINGTON)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (FULCRUM PUBLIC AFFAIRS LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ML STRATEGIES, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (FARRAGUT PARTNERS LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (THE WASHINGTON TAX & PUBLIC POLICY GROUP)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026PatentPatent granted: ANTICANCER COMPOSITIONSUS 12766103
- Oct 20, 2026Patent
- Aug 4, 20268-KDirector or officer changeItem 5.02
- Apr 28, 20268-KShareholder vote resultsItem 5.07
- Feb 11, 202610-KAnnual report (10-K)3 risk factors added, 0 removed
- Nov 12, 2025Risk event
- Sep 9, 20258-KDirector or officer changeItem 5.02
- Jun 10, 20258-KDirector or officer changeItem 5.02
- Apr 30, 20258-KDirector or officer changeItem 5.02
- Apr 30, 20258-KShareholder vote resultsItem 5.07
- Feb 13, 202510-KAnnual report (10-K)0 risk factors added, 2 removed
- Feb 16, 202410-KAnnual report (10-K)1 risk factors added, 2 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Eli Lilly and Company LLY | $79.7B | — | Jun 30, 2026 |
| Merck & Co. MRK | $66.6B | $16.1B | Jun 30, 2026 |
| Pfizer Inc. PFE | $63.7B | $11.0B | Jun 28, 2026 |
| HCA Healthcare HCA | $76.4B | $7.9B | Mar 31, 2026 |
| Humana HUM | $137B | $1.3B | Mar 31, 2026 |
| AbbVie Inc. ABBV | $64.4B | $18.2B | Jun 30, 2026 |
| Centene Corporation CNC | $179B | $8.9B | Jun 30, 2026 |
| Bristol Myers Squibb BMY | $49.2B | $11.4B | Jun 30, 2026 |